511 results about "Lymph nodes size" patented technology

Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.

Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.

An automated method for determining prognosis based on an analysis of abnormality (lesion) features and parenchymal features obtained from medical image data of a patient. The techniques include segmentation of lesions from radiographic images, extraction of lesion features, and a merging of the features (with and without clinical information) to yield as estimate of the prognosis for the specific case. An example is given for the prognosis of breast cancer lesions using mammographic data. A computerized image analysis system for assessing prognosis combines the computerized analysis of medical images of cancerous lesions with the training-based methods of assessing prognosis of a patient, using indicators such as lymph node involvement, presence of metastatic disease, local recurrence, and/or death. It is expected that use of such a system to assess the severity of the disease will aid in improved decision-making regarding treatment options.

Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including one or more (e.g., all) of biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei, and a morphometric measurement of epithelial cytoplasm. In another embodiment, a model that predicts clinical failure post-prostatectomy is provided, wherein the model is based on features including one or more (e.g., all) of dominant prostatectomy Gleason grade, lymph node invasion status, one or more morphometric measurements of lumen, a morphometric measurement of cytoplasm, and average intensity of AR in AR+/AMACR− epithelial nuclei.

A preferred system for detecting an analyte in solid tissue, such as an intact lymph node, in vitro includes a laser arranged to generate a pulsed laser beam into solid tissue, which can be a fully intact lymph node. An acoustic sensor, and preferably at least three acoustic sensors are arranged in different positions to span a three dimensional space, such as in an X, Y and Z coordinate system, to detect photoacoustic signals generated within the lymph node. At least one computer receives signals from the acoustic sensor(s). The computer determines the presence or absence of, and preferably the position of analyte, from the signals and the timing of the signals. A preferred method for detecting an analyte in a lymph node in vitro includes exposing an extracted lymph node to a pulsed laser beam. A photoacoustic signal is sensed. The photoacoustic signal is analyzed to confirm the presence or absence of an analyte in the lymph node. Preferably, multiple photoacoustic signals are sensed from sensors that span a three dimensional space and the position of analyte is also determined.

Techniques include automatically detecting a lymph node in a scanned image of a body without human intervention, using one or more of three approaches. First, a subset of scanned images is determined, which belongs to one anatomical domain. A search region for lymph tissue is in a particular spatial relationship outside an anatomical object in the domain. Second, scanned images are segmented without human intervention to determine a boundary of a particular lymph node. The scanned images and outline data are received. Some of these embodiments automatically segment by determining an external marker, based on the outline data, and an internal marker, based on a geometric center of the outline data or thresholds determined automatically inside detected edges, or both, for a marker-controlled watershed algorithm. Third, based on lymph node data at a particular time, a second scanned image at a different time is segmented automatically, without human intervention.

The present invention is directed to delivery and retention of active agents to targeted lymph nodes in a mammal using a ligand/anti-ligand pair. More particularly, the invention involves methods, compositions, and kits for delivery and retention of active agents to targeted lymph nodes using compositions comprising a ligand-colloid moiety and compositions comprising an anti-ligand. Active agents may be associated with one or more of the colloid, ligand, or anti-ligand. Conjugation of the ligand and anti-ligand after administration permits retention of aggregated colloid complex in targeted lymph nodes.

A method for assigning a lymph node in a medical image with an anatomical name, the method including: identifying landmarks in a medical image; computing features relative to the landmarks given a location of a lymph node in the medical image; and assigning an anatomical name to the location of the lymph node by using a classifier that compares the computed features with classification rules.

The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye/radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and/or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.

Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and/or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.

The present invention relates to a novel gene, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell lines, and in several normal tissues. The full length cDNA encodes a protein of 339 amino acids. Antibodies to the gene product were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of infiltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. Di12 wag also present in IDC-breast cancer patient sera, and its expression level increased markedly if IDC was accompanied by lymph node or distal metastases. As IDC constitutes ~70% of breast cancers seen clinically, the level of Di12 expression is useful for diseases diagnosis predicting disease progression and monitoring a therapeutic treatment.

A steerable sonohysterographic injection catheter for identifying sentinel lymph nodes in uterine cancer patients includes a tubular shaft housing a needle extendible therefrom. The needle is preferably sized for intrauterine insertion and configured to deliver a fluid such as a contrast media to a tumor location. The catheter preferably includes a sealing device such as a selectively inflatable balloon disposed at a position along the outside of the catheter. The sealing device is configured for placement at an opening of a patient's cervix to prevent the leaking of the contrast media out of the uterus through the cervix. The distal end of the catheter is steerable so as to allow the tip of the needle to be positioned substantially near the tumor location.

A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.

A composition is provided accompanying nonoparticles having diameters in the range of about 100 to 800 nanometers with hollow cores and outer shells with mechanical properties such that they rupture on exposure to predetermined ultrasound energy. The composition is useful for identifying sentinel lymph nodes.

The present invention provides human involucrin (hINV) sequences having tissue specific and cell type specific promoter activity. The sequences provided herein direct expression to suprabasal cells of stratifying epithelia. The invention further provides methods for the production of transgenic animals which contain a hINV promoter sequence which directs the expression of human papillomavirus 16 oncogenes (or other oncogenes). These animals display cervical and epidermal hyperplasias as well as cancer of the trachea, esophagus, colon, epidermis, anus/rectum, lymph nodes, spleen and lung. The animals of the invention provide a useful model for screening potential anti-neoplastic compounds, carcinogens, and co-carcinogens for a number of cancers.

A method for entrapping migratory antigen presenting cells (APCs) and particularly Langerhans cells (LCs,) in vivo is provided. The method entails creating an artificial gradient of APC-attracting chemotactic factor in the homing path of APCs in vivo. Also provided is a composition for entrapping APCs and particularly, migratory LCs. In addition, a method for loading APCs in situ with antigen is provided. The method comprises entrapping APCs in vivo and subsequently loading the APCs in situ with antigen. Correspondingly, a composition for loading APCs in situ is also provided. Further provided is a method for stimulating the migration of entrapped APCs to draining lymph nodes. The ability to stimulate the migration of entrapped APCs to draining lymph nodes is useful, inter alia, for regulating an immune response in a subject. In addition, an in situ APC-based vaccine is provided which does not require any time-consuming, costly ex vivo manipulations.

The invention provides systems, methods and a node accessing and anchoring device, comprising an elongated shaft, a tissue cutting member, at least one anchoring element extending from a position at or near the distal end of the shaft; and a radiation detector. The radiation detector is effective to locate and identify sentinel lymph nodes following injection of radioactive material into a primary lesion site within a patient. The tissue cutting member, which may be activated with radio frequency energy, is effective to allow access of the elongated shaft to a sentinel lymph node. The anchoring elements are effective to anchor the device to or adjacent a sentinel lymph node accessed by the device. Anchoring elements may assume radially, longitudinally, or mixed radially and longitudinally curved or coiled configurations when deployed.